MARKET

AKRO

AKRO

Akero
NASDAQ

Real-time Quotes | Nasdaq Last Sale

30.01
-1.04
-3.35%
After Hours: 34.44 +4.43 +14.76% 19:58 01/26 EST
OPEN
31.26
PREV CLOSE
31.05
HIGH
31.40
LOW
29.49
VOLUME
255.97K
TURNOVER
--
52 WEEK HIGH
41.16
52 WEEK LOW
10.78
MARKET CAP
1.04B
P/E (TTM)
-13.8897
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Akero Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will presen...
Business Wire · 01/04 21:05
Akero Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will presen...
BusinessWire · 01/04 18:05
Is AKRO A Good Stock To Buy Now?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bou...
Insider Monkey · 12/13/2020 03:07
Akero Therapeutics To Present At Evercore ISI 3rd Annual HealthCONx Virtual Conference Dec. 3
Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today
Benzinga · 11/24/2020 21:09
Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference
Business Wire · 11/24/2020 21:05
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.
Benzinga · 11/15/2020 15:14
Akero Presents Additional Positive Data From Phase 2a BALANCED Study Demonstrating Potential Of Efruxifermin As Foundational NASH Monotherapy
Akero Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy Data to be presented at the Presidential Plenary Talk at The Liver
Benzinga · 11/13/2020 13:02
Akero Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy
Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced the presentation of additional data analysis from the Phase 2a BALANCED study at the Presidential Oral Plenary Session at The Liver Meeting®. The data continue to demonstrate the potential of efruxifermin (EFX) as a foundational monotherapy for patients with non-alcoholic steatohepatitis (NASH).
Business Wire · 11/13/2020 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKRO. Analyze the recent business situations of Akero through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AKRO stock price target is 60.29 with a high estimate of 79.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 126
Institutional Holdings: 29.29M
% Owned: 84.35%
Shares Outstanding: 34.72M
TypeInstitutionsShares
Increased
40
9.20M
New
34
586.16K
Decreased
23
2.65M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Non-Executive Chairman/Independent Director
Mark Iwicki
President/Chief Executive Officer/Director
Andrew Cheng
Co-Founder/Chief Operating Officer/Executive Vice President
Jonathan Young
Co-Founder/Chief Scientific Officer
Timothy Rolph
Chief Financial Officer/Executive Vice President
William White
Other
Kitty Yale
Independent Director
Tomas Heyman
Non-Executive Independent Director
Kevin Bitterman
Non-Executive Independent Director
Seth Harrison
Non-Executive Independent Director
Jane Henderson
Non-Executive Independent Director
Graham Walmsley
  • Dividends
  • Splits
  • Insider Activity
No Data
About AKRO
Akero Therapeutics Inc. is a cardio-metabolic non-alcoholic steatohepatitis (NASH) company. The Company is focused on developing medicines designed to restore metabolic balance and improve the overall health of patients with NASH. Its lead product candidate is Efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). Efruxifermin is designed to address the processes underlying NASH pathogenesis, with the potential to restore healthy fat metabolism in the liver, reduce hepatocyte stress, mitigate inflammation and resolve fibrosis. It is developing Efruxifermin in a separate cohort evaluating treatment of patients with compensated cirrhosis (F4).

Webull offers kinds of Akero Therapeutics Inc stock information, including NASDAQ:AKRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKRO stock methods without spending real money on the virtual paper trading platform.